Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi To Manufacture Orexigen’s Contrave | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi To Manufacture Orexigen’s Contrave

Expands existing commercial supply network

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Orexigen Therapeutics, Inc. has entered into a commercial supply agreement with Sanofi for the manufacture of Contrave (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for territories outside North America. Sanofi will manufacture Contrave tablets at one of several facilities in France.
 
“We are pleased to engage a manufacturer with Sanofi’s scale and expertise,” said Michael Narachi, chief executive officer of Orexigen. “This agreement expands and diversifies our existing commercial supply network and will help ensure we will be ready to supply Contrave globally if approved.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics